3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
11
Phase 2
9
Phase 1/2
3
Phase 4
2
Phase 1
2
Phase 2/3
1
Status
Active not recruiting
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Lymphoma
2
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Leukemia
1
Interventions
Docetaxel
7
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
5
Prednisone
5
Androgen Antagonists
5
gallium 68 PSMA-11
4
enzalutamide
3
bicalutamide
3
Triptorelin Pamoate
3
Radiosurgery
3
Leuprolide
3
Goserelin
3
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
3
abiraterone
2
Zoledronic Acid
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Mitoxantrone
2
Flutamide
2
Celecoxib
2
Abiraterone Acetate
2
satraplatin
1
relugolix
1
pertuzumab
1
nilutamide
1
maltodextrin
1
luprolide acetate gel depot
1
histrelin
1
genistein combined polysaccharide
1
fluciclovine F-18
1
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Prostatic Neoplasms
×
Prednisolone
×
Clear all
NCT00268476
2023-04-18
STAMPEDE
Medical Research Council
Phase 2/3
Active not recruiting
11,992 enrolled